Kumar R
Physiol Rev. 1984 Apr;64(2):478-504. doi: 10.1152/physrev.1984.64.2.478.
Synthesis of 1,25(OH)2D3 is controlled by numerous factors. The major ones, however, are the circulating amounts of parathyroid hormone (the secretion of which is stimulated by low serum calcium), serum or extracellular fluid phosphorus concentrations, circulating levels of 1,25(OH)2D3 itself, and perhaps serum calcium directly. Many of the other factors noted have effects in vitro only or effects that are observed inconsistently or in one species only. Thus, in low-calcium states, 1,25(OH)2D3 synthesis increases because of increased parathyroid hormone activity. Parathyroid hormone may stimulate 1,25(OH)2D3 synthesis directly or via alterations (a decrease) in serum phosphorus or both. Low serum phosphorus will stimulate 1,25(OH)2D3 synthesis independent of parathyroid hormone levels. Low serum calcium may directly stimulate 25(OH)D3 1 alpha-hydroxylase activity independently of parathyroid hormone. In general terms the vitamin D-endocrine system tends to correct abnormalities in calcium and phosphorus homeostasis. The further metabolism of 1,25(OH)2D3 to other metabolites appears to be mainly a degradative or excretory process. Currently there is no evidence that 1,25(OH)2D3 must itself be altered to other metabolites prior to inducing intestinal calcium transport or bone mobilization. The processes involved in the excretion of 1,25(OH)2D3, such as side-chain oxidation and biliary excretion, are not regulated by serum calcium, phosphorus, or 1,25(OH)2D3 levels. The biliary excretion pathway is also unsaturable over a very wide range and not regulated by calcium, phosphorus, or vitamin D3. Therefore these processes, which account for a large part of the metabolism of 1,25(OH)2D3, are largely unregulated by factors that control the synthesis of 1,25(OH)2D3 and regulate the formation of other calcium-controlling hormones. Other processes involved in the metabolism of 1,25(OH)2D3, such as 24-hydroxylation and 26-hydroxylation, occur in normocalcemic and normophosphatemic states. 24-Hydroxylation is also induced by 1,25(OH)2D3, which benefits the organism, because excessive 1,25(OH)2D3 in various tissues can be altered to a less active metabolite, 1,24,25(OH)3D3. Although there is still no evidence concerning the regulation of C-24 oxidation by dietary calcium and phosphorus levels, the fact that this process is induced by 1,25(OH)2D3 suggests that the metabolic pathway functions in much the same manner as the 24-hydroxylation pathway. The formation of 1,25(OH)2D3-26,23-lactone occurs in normocalcemic states and in situations in which 1,25(OH)2D3 has been administered.
1,25(OH)₂D₃的合成受多种因素控制。然而,主要因素是甲状旁腺激素的循环量(低血清钙会刺激其分泌)、血清或细胞外液磷浓度、1,25(OH)₂D₃自身的循环水平,或许还有血清钙直接发挥作用。所提及的许多其他因素仅在体外有作用,或者其作用并不一致,或者仅在某一物种中观察到。因此,在低钙状态下,由于甲状旁腺激素活性增加,1,25(OH)₂D₃的合成会增加。甲状旁腺激素可能直接刺激1,25(OH)₂D₃的合成,或者通过血清磷的改变(降低)或两者兼而有之来实现。低血清磷会独立于甲状旁腺激素水平刺激1,25(OH)₂D₃的合成。低血清钙可能独立于甲状旁腺激素直接刺激25(OH)D₃ 1α-羟化酶活性。一般而言,维生素D内分泌系统倾向于纠正钙和磷稳态的异常。1,25(OH)₂D₃进一步代谢为其他代谢产物的过程似乎主要是一个降解或排泄过程。目前没有证据表明1,25(OH)₂D₃在诱导肠道钙转运或骨动员之前必须自身转变为其他代谢产物。1,25(OH)₂D₃的排泄过程,如侧链氧化和胆汁排泄,不受血清钙、磷或1,25(OH)₂D₃水平的调节。胆汁排泄途径在非常宽的范围内也是不饱和的,并且不受钙、磷或维生素D₃的调节。因此,这些占1,25(OH)₂D₃代谢很大一部分的过程,在很大程度上不受控制1,25(OH)₂D₃合成并调节其他钙调节激素形成的因素的调节。1,25(OH)₂D₃代谢的其他过程,如24-羟化和26-羟化,发生在血钙正常和血磷正常的状态下。24-羟化也由1,25(OH)₂D₃诱导,这对机体有益,因为各种组织中过量的1,25(OH)₂D₃可以转变为活性较低的代谢产物1,24,25(OH)₃D₃。尽管仍然没有关于饮食中钙和磷水平对C-24氧化调节的证据,但这一过程由1,25(OH)₂D₃诱导这一事实表明,该代谢途径的功能与二十四羟化途径非常相似。1,25(OH)₂D₃ - 26,23-内酯的形成发生在血钙正常的状态以及给予1,25(OH)₂D₃的情况下。